New technologies to accelerate ADC design

Optimizing ADCs via payload selection and linker design

12

December

  • 3:00PM London
  • Free

Why attend?

ADCs represent a new era in targeted cancer therapy, with 15 approved drugs currently on the market. However, more than 100 discontinued programs and a similar number of active clinical trials also underscore the challenges in ADC design. Gaining a deeper understanding of the mechanisms and factors contributing to ADC efficacy and toxicity is essential for accelerating drug development. AI-based tools can help streamline this process by scaling up hypothesis exploration, optimizing antibody and payload selection for patients, and designing linkers to complete the molecules.

The webinar will be hosted by Eleni Tokali, joined by Daniel Veres, Co-founder and CSO of Turbine, who will discuss how modeling payload-driven resistance can improve ADC-patient matching. Guest speaker Hassan Naseri, Scientific & Next Generation Computing R&D Lead at Accenture, will present how Accenture’s AI-driven solutions support their partners in designing cleavable linkers that connect payloads to antibodies.

Join us to explore the expanding ADC market, its primary challenges, and leading machine learning approaches that address these issues!

Learning Objectives:

  • Overview of the ADC scenery and market outlook
  • Challenges in ADC design
  • How can simulations help in understanding payload response and matching them to the right patients?
  • How can AI-driven tools help in designing cleavable linkers for ADCs?

Speakers

Select a speaker to learn more

Back
Daniel Veres, MD, PhD
CSO, Co-founder, Turbine

​​As a medical doctor specializing in cancer research, Daniel helps design innovative and lasting cancer treatments by translating Turbine’s computational findings into clinical insights. His primary responsibility is to understand complex scientific and medical challenges, guiding biologists, translational scientists, and data scientists in generating new discoveries that drive more effective treatments to patients.
 

​Daniel holds a PhD and has extensive experience in systems biology. His years at Turbine have deepened his expertise in building accurate models of complex biological processes, such as the payload response of ADCs.​ 

Next speaker
Back
Hassan Naseri, PhD
Scientific & Next Generation Computing R&D Lead, Accenture

Hassan Naseri leads R&D in Next Generation Computing for Accenture Innovation. He manages projects in quantum computing, high-performance computing, scientific modelling and simulations, and networking. Hassan joined Accenture in 2018,  where his first role was leading an AI team that delivered innovative project in computer vision, network optimization, and AI-based automation. Prior to Accenture, Hassan worked as a scientist in academia, building novel algorithms for sensor networks and mobile devices using AI, optimization, and simulation techniques. He received his Ph.D. in Signal Processing Technology in 2018.

Next speaker
Back
Eleni Tokali
Pharmaceutical Analyst, GlobalData Plc

Eleni Tokali, MPharm, MPH, is a Drug Intelligence Analyst at GlobalData. Her primary responsibilities include managing and maintaining GlobalData’s Drugs Database, analyzing drug pipeline information and producing analytical market insight reports. Additionally, Eleni provides timely client support and performs database quality checks. Prior to joining GlobalData, Eleni worked as a registered pharmacist under the General Pharmaceutical Council (GPhC). Eleni has a firm knowledge of pharmaceutical industry dynamics as well as global public health perspectives. Eleni holds a Master of Pharmacy from the University of Brighton and a Master of Public Health from King's College London.

Next speaker

Enquiry